Graffinity Pharmaceuticals GmbH And Boehringer Ingelheim Pharmaceuticals, Inc. Enter Into Drug Discovery Research Agreement

HEIDELBERG, Germany--(BUSINESS WIRE)--Sept. 7, 2006--Graffinity Pharmaceuticals GmbH announced today that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. which involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of various novel small molecule hit series against multiple drug targets. Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify and evolve small molecule hit structures focusing on compounds with novel modes of action. Financial details of the transaction were not disclosed.

Back to news